Beam Picks Crowded AAT Field To Prove Its In Vivo Gene Editing
Base Editing Could Trump Existing Approaches
Executive Summary
With its first US study for a base-edited CAR-T therapy now back on track, Beam Therapeutics is gearing up to begin studies of its first in vivo candidate, BEAM-302, next year in AAT.